Our Technology

Engineering smarter immune cells with built-in intelligence

Technology Overview

At NeXell Therapeutics, we're pioneering a new generation of immune cell therapies by equipping immune cells with built-in intelligence and multi-level auto-switches to enable self-regulation and dynamic adjustment in response to the diverse and evolving nature of cancers.

NeXell Technology Platform Diagram

Our platform integrates multiple levels of control to create smarter, safer, and more effective cell therapies.

Our technology addresses the key limitations of current cell therapies:

  • Limited efficacy in solid tumors: By engineering cells that can overcome the hostile tumor microenvironment
  • Safety concerns: Through multi-level auto-switches that enable precise control of immune cell activity
  • Short durability: By preventing exhaustion and enhancing persistence of therapeutic cells
  • Manufacturing challenges: Short adds-on to the construct - facilitating their cell delivery

Core Technology Platform

Built-In Intelligence

Our platform equips immune cells with sophisticated sensing and response mechanisms that allow them to:

Sense the Environment

Detect tumor-specific signals and distinguish between healthy and cancerous tissues with high precision.

Adapt Dynamically

Adjust activity levels based on the presence and intensity of specific signals.

Resist Suppression

Maintain functionality even in the immunosuppressive environment of solid tumors.

Persist Longer

Avoid exhaustion mechanisms to provide durable therapeutic effects.

Key Benefits

Enhanced Targeting

Precise recognition of cancer cells while sparing healthy tissues, reducing off-target effects.

Improved Safety

Self-regulating activity reduces cytokine release syndrome and neurotoxicity, common side effects of current therapies.

Greater Efficacy

Ability to overcome immunosuppressive tumor microenvironments found in solid tumors.

Extended Durability

Resistance to exhaustion mechanisms, leading to longer-lasting therapeutic effects.

Versatile Platform

Compatible with various immune cell types, CAR designs and other therapeutic payloads.

Streamlined Manufacturing

Short adds-on to the construct - facilitating their cell delivery.

Applications

Blood Cancers

Enhanced versions of current CAR-T therapies with improved safety profiles and durability for leukemias, lymphomas, and multiple myeloma.

Solid Tumors

Novel cell therapies designed to overcome the unique challenges of solid tumors, including breast, lung, colorectal, and pancreatic cancers.

Combination Approaches

Intelligent cell therapies that can work synergistically with other treatment modalities, including checkpoint inhibitors and targeted therapies.

Future Directions

Potential applications beyond oncology, including autoimmune disorders and infectious diseases, leveraging the same platform technology.

Intellectual Property

Our innovative technology is protected by 5 provisional patents covering our proprietary auto-switch mechanisms, multi-level control systems, and novel cell engineering approaches. This robust IP portfolio safeguards our unique position in the cell therapy landscape and provides a strong foundation for our development programs.

Interested in Our Technology?

Learn more about partnership opportunities or discuss potential applications.

Contact Our Team Meet Our Experts